Skip to main content

Table 10 Any malignancy adverse events

From: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

Adverse Event

n/patient-years of exposure (Incidence Rate per 100 Patient-years†)

 

Sitagliptin

100 mg

Non-exposed

Difference between Sitagliptin and

Non-exposed (95% CI)*

Any malignancy

46/4690 (1.0)

40/3930 (1.0)

-0.0 (-0.5, 0.4)

  1. n = number of patients with ≥ 1 occurrence of the endpoint; CI = confidence interval;
  2. †100 * (number of patients with ≥ 1 event/person years of follow-up time).
  3. * Between-group difference and 95% CI based on stratified analysis. Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.